Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution
Strata (Nasdaq: SRTA) entered a secured, asset-based revolving credit agreement with JPMorgan Chase for up to $30.0 million, with an accordion to $50.0 million subject to conditions.
Rhea-AI Summary
Strata (Nasdaq: SRTA) entered a secured, asset-based revolving credit agreement with JPMorgan Chase for up to $30.0 million, with an accordion to $50.0 million subject to conditions. The ABL Facility was undrawn at closing and will support future acquisitions. Owned aircraft are excluded from the collateral package and remain unencumbered, preserving financing optionality. Company executives said the facility improves capital efficiency and enables continued tuck-in acquisition execution in the clinical perfusion and organ transplant logistics space.
Positive
- Established a $30.0M asset-based revolving credit facility
- Facility expandable to $50.0M subject to conditions
- Facility was undrawn at close, limiting immediate interest cost
- Owned aircraft excluded from collateral, preserving financing optionality
- Explicit purpose to fund acquisitions and accelerate growth
Negative
- Facility is secured, which may encumber eligible assets (excluding aircraft)
- Expansion to $50.0M is conditional, not guaranteed
Details
News Market Reaction – SRTA
On Feb 5, the day this news came out, SRTA closed 6.18% below the previous close.
Data tracked by StockTitan Argus for the Feb 5 session.
Key Figures
- ABL Facility size
- $30.0 million
- Secured, asset-based revolving credit facility with JPMorgan Chase Bank
- ABL Facility upsizing capacity
- $50.0 million
- Maximum size subject to certain conditions in the credit agreement
Previous Acquisition Reports
-
Completed Keystone Perfusion acquisition with updated 2025 revenue and EBITDA guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
asset-based revolving credit financial
abl facility financial
collateral package financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
$30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to$50 million , subject to certain conditions- Owned aircraft excluded from collateral package and remain unencumbered
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), a leading provider of logistics and medical services in the organ transplant industry, today announced that the Company has entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans in aggregate principal amount of up to
“This facility will improve Strata’s capital efficiency, enabling deployment of more cash towards attractive acquisition opportunities,” said Amir Cohen, Strata’s Chief Accounting and Integration Officer. “By leaving our owned aircraft fleet unencumbered, we are maintaining significant optionality for additional financing in the future.”
“We have a strong track record of successful tuck-in acquisitions in the clinical perfusion space,” said Mat Schneider, CFO of Strata’s Clinical division and VP, IR. “This new facility will enable us to continue executing on our time-tested playbook to accelerate growth.”
About Strata Critical Medical, Inc.
Strata is a time-critical logistics and medical services provider to the U.S. healthcare industry. We operate one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery.
Strata’s core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands.
For more information, visit www.srta.com.
Contacts
Mathew Schneider
investors@srta.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.